Scarica l'app Stockscreener
233.91
1.12%
-2.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$236.56
Aprire:
$236.9
Volume 24 ore:
6.54M
Relative Volume:
1.23
Capitalizzazione di mercato:
$413.22B
Reddito:
$58.33B
Utile/perdita netta:
$3.73B
Rapporto P/E:
111.32
EPS:
2.1013
Flusso di cassa netto:
$18.24B
1 W Prestazione:
+6.03%
1M Prestazione:
+10.41%
6M Prestazione:
+16.00%
1 anno Prestazione:
+19.68%
Intervallo 1D:
$233.71
$238.84
Intervallo di 1 settimana:
$219.79
$244.81
Portata 52W:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-09-17 | Aggiornamento | Berenberg | Hold → Buy |
| 2025-08-12 | Ripresa | Piper Sandler | Overweight |
| 2025-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Downgrade | Citigroup | Buy → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-04 | Aggiornamento | Argus | Hold → Buy |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
Can AbbVie Inc. stock outperform in 2025 bull marketMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Why AbbVie Inc. stock is in analyst buy zoneTrade Entry Summary & Technical Pattern Alert System - newser.com
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN
Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance - MSN
AbbVie updates 2025 earnings guidance to reflect $2.7 billion IPR&D expense - Investing.com
AbbVie trims annual profit forecast after expected $2.7 billion R&D hit - Reuters
AbbVie (ABBV) Projects Lower Q3 Earnings Due to IPR&D Costs - GuruFocus
AbbVie (ABBV) Anticipates Financial Impact from Third Quarter Ex - GuruFocus
ABBV Stock Outlook Revised for FY25 - GuruFocus
ABBV Surpasses Earnings Expectations with Strong Q3 Performance - GuruFocus
AbbVie expects $2.7 billion R&D charge in third quarter - The Mighty 790 KFGO
AbbVie sees negative Q3, full-year impact from IPR&D and milestones expense - MSN
AbbVie Says $2.7 Billion in Costs Seen Cutting Q3 EPS by $1.50 - MarketScreener
AbbVie expects $2.7 billion R&D charge in third quarter, lowers annual profit forecast - MarketScreener
AbbVie sees $1.50 per share unfavorable impact in Q3 from milestones expense - TipRanks
AbbVie expects Q3 earnings to include $2.7 billion IPR&D expenseSEC filing - MarketScreener
AbbVie reports $2.7 billion IPR&D expense to impact Q3 earnings - StreetInsider
St Louis Financial Loads Up on AbbVie (ABBV) With 14,600 Shares Buy - The Globe and Mail
What drives AbbVie Inc stock priceReal Estate Investment Trusts & High Return Capital Strategies - earlytimes.in
B of A Securities Maintains AbbVie (ABBV) Neutral Recommendation - Nasdaq
AbbVie: Wins Accumulating While We Wait For Next BD Steps (NYSE:ABBV) - Seeking Alpha
TD Cowen Adjusts Price Target on AbbVie to $280 From $250, Maintains Buy Rating - MarketScreener
Bernstein Remains a Hold on AbbVie Inc. (ABBV) - MSN
Can AbbVie Inc. stock surprise markets with earnings2025 Technical Overview & Technical Buy Zone Confirmation - newser.com
AbbVie invests $70M in Worcester facility, and other life sciences news - The Business Journals
What to do if you’re stuck in AbbVie Inc.Portfolio Risk Report & Daily Chart Pattern Signal Reports - newser.com
Why AbbVie Inc. stock could be next leader2025 Market WrapUp & Safe Entry Point Identification - newser.com
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why - sharewise.com
Bain Set to Face Claims Over Cerevel Trades Before AbbVie Sale - Bloomberg Law News
Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com
AbbVie (ABBV) Kidney Disease Therapy Garners FDA Fast Track Stat - GuruFocus
AbbVie’s Phase 2 HIV Study Completion: Potential Market Impact - TipRanks
AbbVie to Host Third-Quarter 2025 Earnings Conference Call - Yahoo Finance
AbbVie downgraded to Hold from Buy at HSBC (yesterday) - TipRanks
AbbVie (ABBV) Surges on Expansion and Industry Developments - GuruFocus
Why AbbVie Stock Cruised to an Almost 6% Gain Today - Yahoo Finance
AbbVie (ABBV) Downgraded by HSBC, Shares Continue to Climb - GuruFocus
Why AbbVie (ABBV) Stock Is Trading Up Today - Yahoo Finance
AbbVie downgraded at HSBC due to limited upside - MSN
AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability - msn.com
HSBC Downgrades AbbVie (ABBV) Rating to Hold on October 1, 2025 - GuruFocus
AbbVie begins $70M Massachusetts expansion as pharmaceutical tariffs kick in - Crain's Chicago Business
AbbVie Stock Is Just What the Doctor Ordered - MSN
AbbVie breaks ground on $70m US biologics site amid Trump pressure - Pharmaceutical Technology
AbbVie Stock Is Just What The Doctor Ordered - Barchart.com
2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi - Yahoo Finance
ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer - The Globe and Mail
Natrelle® Awarded Supplier Agreement from Vizient - PR Newswire
Big pharma firms announce direct-to-consumer sales and price cuts in U.S. - Reuters
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever - The Motley Fool
AbbVie (ABBV) Invests $70M in Worcester Expansion to Boost Biolo - GuruFocus
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.43%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):